- FDA approves Johnson & Johnson’s nasal spray for depression as standalone treatment CNBC
- Controlled drug Ketamine a lifeline for patients with severe depression in S’pore The Straits Times
- Johnson & Johnson Gets FDA OK For Spravato as Monotherapy MarketWatch
- Safety and Feasibility of Intranasal Ketamine in Depression Treatment Physician’s Weekly
- US FDA approves J&J’s ketamine-based therapy to treat depression Reuters.com
Credit: Source link
